Ramelteon

Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].

Product Specifications

CAS Number

[196597-26-9]

Product Name Alternative

TAK-375

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Melatonin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/ramelteon.html

Purity

99.87

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NCC[C@H]1C2=C(C=CC3=C2CCO3)CC1)CC

Molecular Formula

C16H21NO2

Molecular Weight

259.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Kato K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48 (2) :301-310.|[2]Mayer G, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32 (3) :351-360. |[3]Hirai K, et al. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms. 2005;20 (1) :27-37.|[4]Miyamoto M, et al. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep. 2004;27 (7) :1319-1325.